



Strong Q1 growth driven by Specialty Care, Vaccines and CHC

Date Published: Thursday, 27 Apr 2023

DETAILED NEWS

- In Q1 2023, Sanofi reported a 5.5% sales growth at CER and an 11.9% increase in business EPS.
- Specialty Care sales surged by 18.3%, driven by Dupixent, while Rare Disease Vaccines rose by 15.2% due to the recovery of Booster and Travel vaccines and COVID vaccine shipments in Europe.
- Sanofi made progress in Corporate Social Responsibility, partnering with the Ghana Ministry of Health and setting Net Zero by 2045 goals, validated by SBTi.
- Full-year 2023 business EPS guidance remains confirmed, with an expectation of low single-digit growth at CER, barring unforeseen major adverse events, and an estimated -5.5% to -6.5% currency impact on business EPS applying average April 2023 exchange rates.

INSIGHTS

- In Q1 2023, Sanofi observed a significant growth in their sales and business EPS, with a rise of 5.5% and 11.9% respectively.
- The increase indicates a positive business performance and potential growth in future quarters.
- The company's Specialty Care sales witnessed an impressive surge of 18.3%, primarily propelled by the performance of Dupixent.
- This surge shows the product's strong market demand and Sanofi's successful performance in the Specialty Care segment.
- The Rare Disease Vaccines segment also saw a substantial rise of 15.2%, driven by the recovery of Booster and Travel vaccines and COVID vaccine shipments in Europe.

- ↪ This indicates that the company's vaccine business is rebounding post-pandemic and making significant contributions to the overall growth.
- ↪ Sanofi has been actively participating in Corporate Social Responsibility efforts, as seen by their partnership with the Ghana Ministry of Health and their Net Zero by 2045 goals.
- ↪ These steps not only enhance the company's reputation but also position it as a socially responsible entity.
- ↪ Despite the uncertainties, the company's full-year 2023 business EPS guidance remains confirmed, expecting a low single-digit growth at CER.
- ↪ However, there is an anticipated currency impact of -5.5% to -6.5% on business EPS, applying average April 2023 exchange rates.
- ↪ This suggests that while the company expects growth, it is also prepared for potential currency-related risks.